Drug intelligence / Profile preview

H021

Development stage: Phase 2
Lead developer: Carephar
Modality: Small Molecules
Administration: Oral

Overview

H021 is an orally administered small molecule drug initially developed by Jiangsu Carephar Pharmaceutical. It is currently in Phase 1 clinical trials, with studies focused on evaluating its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy adult subjects. The drug is being investigated for immune system-related therapeutic areas, including Crohn's disease, colic, bowel dysfunction, and ulcerative colitis. Clinical trials are assessing both single and multiple ascending doses as well as the impact of food on its absorption and metabolism.

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on H021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H021.

Explore the full profile